Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted

作者：Takayuki, Yasuda; Masayuki, Nitta; Takashi, Komori; Tatsuya, Kobayashi; Kenta, Masui; Takashi, Maruyama; Tatsuo, Sawada; Yoshihiro, Muragaki; Takakazu, Kawamata

来源：Neuropathology, 2018, 38(1): 41-46.

DOI：10.1111/neup.12406

<jats:p>Herein, we present a rare case of gliosarcoma arising from oligodendroglioma, isocitrate dehydrogenase (<jats:italic>IDH</jats:italic>) mutant and 1p/19q codeleted. A 36‐year‐old man presented with a non‐enhanced calcified abnormal lesion on the right frontal lobe. The patient underwent subtotal surgical resection, <jats:styled-content style="fixed-case">PAV</jats:styled-content> chemotherapy (procarbazine, nimustine (ACNU) and vincristine), and fractionated radiotherapy with 50 Gy. The pathological diagnosis was oligodendroglioma, <jats:italic>IDH</jats:italic> mutant and 1p/19q codeleted, <jats:styled-content style="fixed-case">W</jats:styled-content>orld <jats:styled-content style="fixed-case">H</jats:styled-content>ealth <jats:styled-content style="fixed-case">O</jats:styled-content>rganization 2016 grade <jats:styled-content style="fixed-case">II</jats:styled-content>. Six years later, a new enhanced lesion appeared, and the recurrent tumor was surgically removed. Although the histopathological findings indicated gliosarcoma, the recurrent tumor still demonstrated the <jats:italic>IDH</jats:italic> mutation and 1p/19q codeleted. Thus, the recurrent tumor was considered to originate from oligodendroglioma, rather than being newly generated after chemoradiotherapy. Interestingly, the second recurrent tumor responded well to temozolomide chemotherapy. Based on the findings of this case, oligodendrogliomas have the potential for mesenchymal transformation on progression, while keeping their genotype.</jats:p>

• 出版日期2018-2
• 单位南方医科大学